Resolutions of Nightingale Health Plc’s Annual General Meeting and Board of Directors
Company release
28 October 2021 at 6:15 p.m. (EEST)
Nightingale Health Plc’s Annual General Meeting, held on 28 October 2021, adopted the financial statements and discharged the members of the Board of Directors and the CEO from liability for the financial period of 1 July 2020–30 June 2021. The Annual General Meeting approved in an advisory decision the remuneration report and remuneration policy of governing bodies.
Use of the profit shown on the balance sheet and the payment of dividend
The General Meeting resolved in accordance with the proposal of the Board of Directors that, based on the balance sheet adopted for the financial period ended on 30 June 2021, no dividend will be distributed.
The Board of Directors and the Auditor
The number of members of the Board of Directors was confirmed to be seven members. Tom Jansson, Antti Kangas, Olli Karhi, Lotta Kopra, Leena Niemistö, Timo Soininen and Teemu Suna were re-elected as members of the Board of Directors.
The members of the Board of Directors are paid a monthly remuneration of EUR 2,000.
Authorised Public Accounting firm PricewaterhouseCoopers Oy was elected as the Auditor with Valtteri Helenius as the Responsible Auditor. The remuneration of the Auditor will be paid in accordance with a reasonable invoice approved by the company
Decisions by the Board of Directors of Nightingale Health Plc
The organisational meeting of the Board of Directors elected from among its members Timo Soininen as its Chair. The other members of the Board of Directors are Tom Jansson, Antti Kangas, Olli Karhi, Lotta Kopra, Leena Niemistö and Teemu Suna.
For further information, please contact:
Teemu Suna, CEO
ir@nightingalehealth.com
Certified advisor:
Oaklins Merasco Ltd, tel. +358 9 6129 670
About Nightingale
Nightingale Health is a health technology company transforming preventive care. We envisage a world that focuses on keeping people healthy rather than just treating illnesses. The wide-ranging disease risk predictions provided by Nightingale consist of two interconnected factors: The extensive blood analysis technology developed by Nightingale and a large amount of data on health events. Nightingale helps people make better personal health decisions and connects the health industry to offer their services for individuals’ preventative needs. By empowering the world with comprehensive health insights, we accelerate scientific discoveries, industry developments and improve personal health for everyone.
Tags: